TransMedics Group (TMDX) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue reached $173.9 million, up 21% year-over-year, driven by OCS Liver sales, increased NOP usage, and logistics services.

• Net income was $7.3 million ($0.20 per diluted share), while adjusted net income was $10.9 million ($0.30 per diluted share), reflecting higher operating and interest expenses.

• Significant investments were made in people, infrastructure, R&D, and technology to support long-term growth and international expansion.

• Hosted a major symposium, launched the CHOPS system, and entered an agreement with PAD Aviation to build a European transplant logistics network.

• OCS platform remains the only FDA-approved, portable, multi-organ, warm perfusion technology for heart, lung, and liver.

Financial highlights

• Product revenue was $108.0 million (up 22.4% year-over-year); service revenue was $66.0 million (up 19.3% year-over-year).

• Gross margin declined to 58% from 61% year-over-year due to supply chain and inventory investments.

• Adjusted operating profit was $18.1 million (10.4% margin); adjusted net income was $10.9 million.

• Operating expenses rose to $87.9 million, mainly from higher personnel, R&D, and facility costs.

• Cash and equivalents at quarter-end were $461.7 million.

Outlook and guidance

• Full-year 2026 revenue guidance reiterated at $727–$757 million, representing 20–25% growth over 2025, assuming continued OCS adoption and organ utilization.

• Long-term gross margin expected to remain around 60%, with near-term pressure from ongoing investments.

• Operating and capital expenditures expected to rise as commercial and R&D activities scale.

• Management believes current cash is sufficient to fund operations, capex, and debt service for at least 12 months.